Long-term health and treatment outcomes in adult coeliac disease patients diagnosed by screening in childhood by Kivelä, Laura et al.
Long-term health and treatment outcomes in adult celiac disease patients diagnosed by 
screening in childhood 
Laura Kivelä, MD1,2, Alina Popp, MD1,3, Taina Arvola, MD1,4, Heini Huhtala, MSc5, Katri 
Kaukinen, MD6,7, Kalle Kurppa, MD1
Affiliations: 1Center for Child Health Research, University of Tampere and Tampere 
University Hospital; 2Department of Pediatrics, Hospital District of South Ostrobothnia, 
Seinäjoki, Finland; 3Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 
4Department of Pediatrics, Hospital District of Kanta-Häme, Hämeenlinna; 5Faculty of Social 
Sciences, University of Tampere; 6Department of Internal Medicine, Tampere University 
Hospital; 7Celiac Disease Research Center, University of Tampere, Tampere, Finland. 
Corresponding Author: Kalle Kurppa, MD, PhD, Center for Child Health Research, 
University of Tampere and Tampere University Hospital, Lääkärinkatu 1, FI-33014 
University of Tampere, Finland.  
kalle.kurppa@uta.fi 
Funding: This study was supported by the Competitive State Research Financing of the 
Tampere University Hospital, the Foundation for Pediatric Research, the Yrjö Jahnsson 
Foundation, the Mary and Georg C. Ehrnrooth Foundation, the Maud Kuistila Foundation, the 
Maire Rossi Foundation and the Finnish Medical Foundation.  
Conflict of Interest: none 
This is the post print version of the article, which has been published in United european 
gastroenterology journal . 2018, 6 (7), 1022-1031. https://doi.org/10.1177/2050640618778386.
 2 
Background: The diagnostic yield of celiac disease could be improved by screening in at-risk 
groups, but long-term benefits of this approach are obscure. 
Objective: To investigate health, quality of life and dietary adherence in adult celiac patients 
diagnosed in childhood by screening. 
Methods: After throughout evaluation of medical history, follow-up questionnaires were sent 
to 559 adults with childhood celiac disease diagnosis. The results were compared between 
screen-detected and clinically-detected patients, and also between originally asymptomatic 
and symptomatic screen-detected patients. 
Results: 236 (42%) patients completed the questionnaires a median of 18.5 years after 
childhood diagnosis. Screen-detected patients (n=48) had more often celiac disease in the 
family and type 1 diabetes and were less often smokers and members of celiac societies 
compared to clinically-detected patients, whereas the groups did not differ in current self-
experienced health or health concerns, quality of life or dietary adherence. Screen-detected, 
originally asymptomatic patients had currently more anxiety than those presenting with 
symptoms, whereas the subgroups were comparable in other current characteristics.    
Conclusion: Comparable long-term outcomes between screen-detected and clinically-
detected patients support risk-group screening for celiac disease. However, asymptomatic 
patients may require special attention.  
 
Key Words: children, diagnosis, gluten-free diet, long-term follow-up, quality of life, 
screening  
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Key Summary 
Established knowledge on this subject 
• Celiac disease is a common, but significantly under-recognized condition. 
• Screening could be used to improve diagnostic yield, but the long-term benefits of this 
approach remain unclear.  
 
New findings of this study 
• Currently adult patients diagnosed by screening in childhood were comparable to 
those found because of clinical suspicion in a variety of health outcomes, including 
adherence to gluten-free diet and quality of life. 
• There were also no differences in most characteristics between originally 
asymptomatic and symptomatic patients, but the former group had more anxiety in 
adulthood. 
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Introduction 
During recent decades celiac disease has become a common health problem affecting up to 1–
3% of the population.1,2 Unfortunately, due to the diverse clinical presentation, most sufferers 
remain undiagnosed.1,2 Diagnostic efficiency could be improved by risk-group screening, for 
example among relatives of patients and those with type 1 diabetes.3 Supporting early 
diagnosis, screen-detected children may already have advanced disease and a subsequent risk 
of permanent complications such as impaired growth and reduced bone accrual.4–7 Delaying 
diagnosis until later adulthood predisposes to even more severe maladies, including 
osteoporotic fractures and refractory celiac disease.8  
 
Counterweighting the benefits of screening is the burden of demanding treatment. Adhering 
to a gluten-free diet may negatively affect the quality of life, especially in asymptomatic 
patients with satisfactory health prior to diagnosis.9 Despite these challenges, there are some 
evidence that these children can achieve good dietary adherence and quality of life in a short-
term follow-up.7,10–12 However, long-term data in screen-detected celiac disease patients are 
very limited.13,14 It is possible that in puberty the initial “honeymoon period” fades 
concurrently with the new challenges in life, leading to poor compliance and ill-health.15,16 
The paucity of long-term studies has led to prudence when it comes to screening 
recommendations.17 
 
In the present study, we investigated long-term health and treatment outcomes in adult celiac 
disease patients diagnosed in childhood. We were particularly interested in patients detected 
by at-risk group screening, including those with no apparent symptoms.  
 
Methods 
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Patients and study design 
The study was conducted in the Tampere Center for Child Health Research. Data were 
constructed by combining patients’ answers to questionnaires and personal health information 
collected from medical records, and in some cases, by interviews carried out in the context of 
an earlier study.18 The basic cohort comprised 1070 patients gathered from our research 
database,18 supplemented by a search with selected diagnosis codes possibly indicating celiac 
disease in the patient records of Tampere University Hospital, (Figure 1) a tertiary center with 
a catchment area of ≈120.000 children. Patients with a reported diagnosis made <18 years of 
age during 1966–2014 were included for further assessment. After evaluation of medical 
records, 115 patients were found to be deceased and/or have an uncertain diagnosis. Of the 
remaining 955 patients with a proven childhood diagnosis, 559 were currently alive and ≥18 
years and were sent the study questionnaires. A repeat questionnaire was sent to all non-
responders after two months. (Figure 1)  
 
For the subsequent analyses, the responders were divided into 1) those diagnosed via risk-
group screening including patients suffering from type 1 diabetes or other concomitant 
autoimmune disease, or having celiac disease in the relatives, and 2) those found due to 
clinical suspicion. Screen-detected patients were further classified into asymptomatic and 
symptomatic based on the evaluation of symptoms at diagnosis before initiation of gluten-free 
diet. All study variables were compared between the above-mentioned groups.  
 
Altogether 110 healthy adults comprised the control group for comparison of current 
symptoms and quality of life.19 Their median age was 49 (range 23–87) years and 81% were 
females. Controls were recruited among the friends and close neighborhood of known celiac 
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disease patients. None of the controls had suspicion of celiac disease or known celiac disease 
in close relatives. 
 
Medical history 
Medical data were collected regarding the clinical and histological presentation of celiac 
disease at the time of diagnosis. Information was gathered on the main reason for celiac 
disease suspicion and presence of gastrointestinal or extra-intestinal symptoms. Furthermore, 
possible complications, as well as the presence of celiac disease-related or other coexisting 
disease and celiac disease in first-degree relatives were noted. Abnormalities in laboratory 
values or physician’s examination were also recorded, but were considered as signs instead of 
symptoms.  
 
Poor growth was defined as disturbed height and/or weight development compared to 
expected growth as described in detail elsewhere.5 Body mass index was calculated as 
height/weight2 (kg/m2). Anemia at diagnosis was defined based on the age- and gender-
dependent reference values for hemoglobin.  
 
Severity of histological damage was classified based on the pathologic report. In our hospital 
practice, the degree of villous atrophy is evaluated from several well-oriented biopsy samples 
and further categorized as partial, subtotal or total (Marsh IIIa–c).  
 
Questionnaires 
Currently adult patients completed three surveys, including a specifically designed study 
questionnaire and two questionnaires evaluating gastrointestinal symptoms and quality of life. 
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The study questionnaire comprised items on sociodemographic and lifestyle characteristics 
such as work and study situation, membership in a celiac society, regularity of physical 
exercise, smoking, presence of children, and celiac disease in the family. The presence of 
celiac-related comorbidities and other chronic diseases was evaluated. Current self-
experienced health was categorized as excellent, good, moderate or poor; and concerns about 
health as none/minor or moderate/severe. Furthermore, patients reported experience of self-
assessed possibly celiac disease-related symptoms and everyday life restrictions caused by the 
treatment. Adherence to a gluten-free diet was classified as strict, occasional lapses, regular 
lapses or no diet; and frequency of follow-up as regular or none/very occasional.  
 
The Psychological General Well-Being (PGWB) questionnaire evaluates health-related 
quality of life, which is subsequently divided into anxiety, depression, positive well-being, 
self-control, general health and vitality.20 Altogether 22 questions are rated from 1 to 6 higher 
scores representing better well-being. Total score is a sum of all scores the values being 
between 22 and 132, and the sub-dimensions are calculated as sums of scores of selected 
questions. For example, vitality describes person’s energy level, and the score is comprised as 
a sum of questions about overall energy, activity and tiredness, and experience of resting after 
night sleep.20 
 
Gastrointestinal Symptom Rating Scale (GSRS) consists 15 questions, which evaluate 
common gastrointestinal symptoms and their severity.21 Each question is scored with seven-
point Likert scale from asymptomatic (1) to severe symptoms (7). Total score is calculated as 
a mean of all 15 items. Further, the questions are divided to five sub-dimensions being 
abdominal pain, indigestion, diarrhea, constipation and reflux, which are calculated as means 
of selected questions.  
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Ethical aspects 
The Regional Ethics Committee of Tampere University Hospital approved the research 
protocol (Ethical committee code R16091, 05/31/2016), and ethical guidelines of the 1975 
Declaration of Helsinki were conformed. Patients participating earlier interviews or 
answering the questionnaires fulfilled informed consent. 
 
Statistics 
Non-parametric numeric values are reported as medians with quartiles, and compared 
between the groups with Mann-Whitney U or Kruskal-Wallis test. Bonferroni correction was 
used in pair-wise post-hoc comparisons. Categorized values are reported as numbers and 
percentages, and compared with Chi Square or Fisher’s Exact test. Significance was set at P 
value <0.05. Statistical analyses were carried out with SPSS version 23 (IBM Corporation, 
Armonk, NY). Data were available on >90% of patients unless otherwise stated. 
 
Results 
Altogether 237 (42%) currently adult patients answered the questionnaires. (Figure 1) The 
responders were more often girls, suffered less frequently type 1 diabetes and had more celiac 
disease in the family than the non-responders (n=322), while the groups did not differ 
significantly in other diagnostic variables such as clinical presentation and the main reason for 
diagnostic evaluations. (eTable 1) 
 
Of 236 responders with available information on diagnostic approach, 48 (20%) had been 
found by screening and 188 (80%) due to clinical suspicion. (Table 1) Screen-detected 
patients were diagnosed at significantly older age and during more recent years. They also 
 9 
had fewer symptoms and growth disturbances at diagnosis, but although their hemoglobin 
levels were higher, there was no significant difference between the groups in the presence of 
anemia. The groups were also comparable in gender and degree of villous atrophy. (Table 1)  
 
In subgroup analysis, screen-detected patients presenting with symptoms at diagnosis (n=21) 
were younger (9.5 vs 12.1 yr, p=0.098) and more often girls (86% vs 56%, p=0.025) and had 
more anemia (33% vs 7%, p=0.031) than asymptomatic subjects (n=27). The subgroups did 
not differ in the year of diagnosis, presence of growth disturbances, median hemoglobin or 
degree of villous atrophy (data not shown). 
 
In current comparison at a median of 18.5 years (IQR 12.7, 30.7 years) after the diagnosis, the 
presence of celiac disease in the family and type 1 diabetes were more common in screen-
detected patients, whereas they were less often members of celiac societies and current 
smokers than those found due to clinical suspicion. (Table 2) The groups were comparable in 
age, work and study situation, presence of other concomitant diseases and children, frequency 
of physical exercise and body composition (Table 2), as well as in experienced health, 
concerns about health, presence of symptoms, daily restrictions caused by the treatment, 
dietary adherence and implementation of follow-up. (Table 3) There were no differences 
between the subgroups of symptomatic and asymptomatic patients in the afore-mentioned 
variables. (Table 4) 
 
Screen-detected and clinically detected patients were comparable in respect of current quality 
of life and symptoms as measured by PGWB and GSRS, but both groups showed lower 
vitality (Figure 2A) and screen-detected patients more abdominal pain and reflux (Figure 2B) 
compared to non-celiac controls. When the analyses were repeated in the subgroups, PGWB 
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anxiety and vitality scores were lower than controls in those who were asymptomatic at 
diagnosis (Figure 2C), while there were no differences in GSRS (data not shown). Increased 
anxiety was also seen in patients with other than celiac-related co-morbidities such as 
malignancies, eating disorder and depression, and in smokers, whereas coexisting type 1 
diabetes or thyroid disease were not associated to anxiety and it did not correlate with time 
from the diagnosis (data not shown). 
 
Discussion 
Our main finding was that celiac disease patients diagnosed in childhood by screening and 
due to clinical suspicion are comparable in most measured adulthood health outcomes. The 
results give further support to screening among at-risk children. However, a subgroup of 
patients asymptomatic at diagnosis are at an increased risk of later anxiety and may require 
special support during the follow-up. Whether benefits of screening overcome the possible 
burden of the dietary treatment cannot be answered with certainty by this study design, but it 
is important to bear in mind that also asymptomatic screen-detected patients have risk to 
develop permanent complications. 
 
As regards to the rationale of screening, it was of particular importance that we found no 
differences in dietary adherence between screen- and clinically detected celiac disease 
patients. Earlier long-term studies investigating this issue are scant. In a study by Roma et al, 
88% of screen-detected children adhered to a gluten-free diet compared to 58% of the whole 
study cohort after four years on diet.22 Fabiani et al. reported a mere 23% of screen-detected 
adolescents to maintain a strict diet after five years compared to 68% of those found because 
of malabsorptive symptoms.15 Besides these pediatric studies, we and Mahadev et al. have 
observed similar dietary adherence patterns between cohorts of screened and clinically 
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detected adults of whom some were diagnosed as children.23,24 However, subjects with a 
childhood diagnosis were not evaluated separately. A few more adult studies have assessed 
adherence in originally pediatric patients, but it is unclear whether screen-detected subjects 
were included.13,25  
 
Drawing firm conclusions from this limited number of studies is challenging, but adherence is 
likely to be markedly dependent on the variability prevailing in knowledge of celiac disease 
and the availability of gluten-free products.26,27 Furthermore, it is important to realize that 
Fabiani et al. published their study as far back as 2000, since which the gluten-free diet has 
become popular and easier to maintain.28 More studies in different populations are needed, 
but we here demonstrated that, in favorable circumstances, achieving good long-term dietary 
adherence is possible in screen-detected patients. Furthermore, screened patients had similar 
or even better health-related behavior, when for example smoking was less common among 
them. However, one explanation for this could be higher proportion of those with type 1 
diabetes among screen-detected compared to clinically found, since these patients are advised 
to avoid smoking especially strictly to prevent diabetes-associated long-term complications.  
 
A gluten-free diet is necessary to achieve remission in celiac disease, but can be challenging 
in many respects. Here, screen-detected and clinically identified patients did not differ in 
quality of life or experience of everyday life restrictions caused by the treatment. 
Nevertheless, dietary restriction might be particularly burdensome in screen-detected patients, 
who often consider themselves healthy before the diagnosis and may lack the experience of a 
positive treatment response.29,30 Earlier, Fabiani et al. observed screen- and clinically detected 
adolescents to be comparable in the experience of anxiety and depression.15 In addition, van 
Koppen et al. reported comparable quality of life between healthy controls and 32 screen-
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detected children after 10 years on diet.14 However, even at that point these patients were still 
in early adolescence (<15 years) and the treatment mainly the parents´ responsibility.  
 
Clinical presentation and particularly absence of symptoms may affect the experience of a 
celiac disease even more than the original reason for diagnostic evaluations.17 Hitherto the 
lack of evidence on the long-term benefits of screening particularly in asymptomatic patients 
has led to considerable caution, and for example the US Preventive Services Task Force has 
demanded more prospective studies before releasing screening recommendations.17 In 
practice, however, the required studies are particularly laborious and may take decades to 
complete with sufficient power. Our center has a long tradition in celiac disease research, 
which enabled us to obtain an unique cohort of adults diagnosed by childhood screening from 
as far back as the 1970s.18,31. Another issue important to realize when discussing screening is 
that it is not a synonym for absence of symptoms, as many of these patients are not 
asymptomatic but simply unrecognized,7,10,23 as was also seen in almost half of our patients. 
As regards truly asymptomatic cases, it was noteworthy that they did not report more 
restrictions in daily life or most aspects of quality of life.  
 
There are important arguments favoring celiac disease screening already in childhood. 
Notwithstanding the less severe clinical presentation, we observed that screen-detected and 
even asymptomatic children can already have severe histological damage. This confirms our 
earlier findings, and demonstrates that these otherwise unidentified patients are at risk of 
permanent complications similarly to those found in clinical practice.7 In fact, some 
asymptomatic children here already had signs of anemia and poor growth, and others have 
reported such patients to suffer from osteopenia and underachievement.4,32 Furthermore, 
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although more studies are needed, an early initiated gluten-free diet might reduce the risk of 
other autoimmune diseases.33,34 
 
Although most of our results support childhood screening, certain challenges remain. We 
found an absence of symptoms to predispose to increased anxiety in adulthood, which is in 
accord with our previous observation in a small subgroup of asymptomatic adults.9 It is 
logical that these individuals find it difficult to adapt to the diagnosis and life-long dietary 
restriction, particularly if its justification is unclear. Alternatively, owing to the absence of 
warning symptoms, they might be afraid of inadvertent gluten exposure and the subsequent 
development of complications. It is therefore important to explain why treatment could be 
rational in asymptomatic celiac disease, and to underline the good prognosis when dietary 
adherence is successful. 
 
Strengths and limitations 
The major strength of the present study is the large cohort of adults with biopsy-proven celiac 
disease diagnosed in childhood. We also succeeded in collecting comprehensive medical data 
at diagnosis together with a variety of sociodemographic, health and lifestyle factors at 
present. The use of validated questionnaires in the evaluation of symptoms and quality of life 
increases the reliability and generalizability of the results.9,19–21,23,27  
 
There were also limitations. A relatively low response rate to questionnaires predisposes to 
selection bias. This common problem in postal surveys was likely further aggravated by the 
long interval between the diagnosis and the current study. For example, it is possible that 
patients who had better dietary adherence answered more often the questionnaires and thus 
skewed the results. However, the fact that responders and non-responders were comparable in 
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most features reduces the risk of bias. Another limitation was incomplete data in a part of the 
study variables at the time of diagnosis. Finally, the non-celiac controls were older and more 
often females than celiac disease patients, which may affect the comparability of quality of 
life.35 
 
Conclusions 
We provided previously lacking evidence regarding the long-term health outcomes in screen-
detected celiac disease. Of particular importance was that even asymptomatic children can 
attain good adulthood quality of life while maintaining a strict gluten-free diet. However, 
physicians should bear in mind that in some patients the absence of symptoms at childhood 
diagnosis may predispose to later anxiety. We do not regard this as a counterargument to 
screening, but encourage to take clinical presentation into account when planning the long-
term follow-up. At this point we feel that affected children and their families have at least a 
right to be aware of the underlying celiac disease, and be in a position to consider treatment 
options. Without screening a substantial number of sufferers remain undiagnosed, with often 
unrecognized symptoms and an increased risk of complications.   
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Figure Legends 
Figure 1. Flowchart of the study. aPatients were gathered from our research database and 
supplemented by a search in the patient records with ICD-7-10 diagnosis codes K90.0, 579A, 
579.0, 269.00, 269.98 and 286.00 possibly indicating celiac disease; bPatients with incorrect 
diagnosis code were found to have e.g. hemophilia A, cow´s milk allergy, primary lactose 
intolerance or von Willerbrandt disease.  
 
Figure 2. Psychological General Well-Being (A, C) and Gastrointestinal Symptom 
Rating Scale (B) sub-scores in adults. Celiac disease patients were first divided into those 
diagnosed in childhood via risk-group screening (n=48) and due to clinical suspicion (n=188) 
(A-B), and the group of screen-detected patients was then further divided into those who were 
asymptomatic (n=27) and symptomatic (n=21) at diagnosis (C). The corresponding values for 
110 non-celiac adults are shown for comparison. Higher scores indicate either better 
psychological well-being (A, C) or more severe symptoms (B). Differences between the 
groups were evaluated by Kruskal-Wallis test and Bonferroni correction was used in pair-wise 
post-hoc comparisons. Median (horizontal line), IQR (box), and minimum and maximum 
values (vertical line) of the scores are presented for each patient group. 
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Table 1. Characteristics at time of childhood diagnosis in currently adult celiac 
disease patients. 
 Screen-detected patients, n=48 
Clinically detected 
patients, n=188 P value 
Age at diagnosis, median (IQR), years 11.7 (8.1, 14.6) 8.7 (4.5, 13.3) 0.004 
Year of diagnosis, median (IQR) 2000 (1992, 2005) 1997 (1983, 2003) 0.017 
Girls, No. (%) 33 (68.8) 130 (69.1) 0.957 
Symptoms a, No. (%) 21 (43.8) 151 (86.3) <0.001 
Poor growth, No. (%) 8 (17.4) 88 (51.8) <0.001 
Anemia, No. (%) 9 (18.8) 54 (31.2) 0.091 
Hemoglobin, median (IQR), g/l 130 (121, 134) b 123 (114, 131) c 0.015 
Degree of villous atrophy, No. (%)   0.176 
 Partial 15 (34.1) 52 (31.0) d  
 Subtotal 21 (47.7) 62 (36.9) d  
 Total 8 (18.2) 54 (32.1) d  
a Asymptomatic signs such as poor growth, anemia and other laboratory abnormalities excluded. 
b-d Data available only from b 32, c 158, d 168 of patients. 
IQR, interquartile range. 
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Table 2. Current sociodemographic and lifestyle characteristics and 
comorbidities in adult celiac disease patients diagnosed in childhood. 
 Screen-detected patients, n=48 
Clinically detected 
patients, n=188 P value 
Age, median (IQR), years 26.6 (21.1, 35.2) 27.2 (22.1, 38.1) 0.328 
Working full-time, No. (%) 25 (67.6) a 93 (62.0) b 0.530 
Student, No. (%) 19 (39.6) 59 (31.4) 0.281 
Member of celiac society, No. (%) 18 (37.5) 104 (56.5) 0.019 
Celiac disease in the family, No. (%) c 31 (64.6) 72 (40.0) 0.002 
Type 1 diabetes, No. (%) 13 (27.1) 5 (2.7) <0.001 
Thyroidal disease, No. (%) 8 (16.7) 15 (8.2) 0.103 
Other concomitant disease d, No. (%) 24 (50.0) 92 (49.5) 0.947 
One or more children, No. (%) 18 (37.5) 81 (44.0) 0.416 
Current smoking, No. (%) 2 (4.2) 28 (15.2) 0.042 
Quit smoking, No. (%) 10 (21.3) 36 (22.0) 0.921 
Regular physical exercise e, No. (%) 29 (60.4) 111 (59.0) 0.863 
Body mass index, median (IQR), kg/m2 24.6 (22.2, 26.7) 23.4 (21.3, 26.6) 0.198 
ab Data available for only a 37 and b 149 of patients. 
c First degree relatives; d For example other gastrointestinal disease, rheumatic disease, hypertension, 
cancer, osteoporosis, psoriasis, depression, eating disorder or asthma; e ≥3 times per week. 
IQR, interquartile range. 
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Table 3. Current health experiences, dietary adherence and follow-up in adult celiac 
disease patients diagnosed in childhood.  
 Screen-detected patients, n=48 
Clinically detected 
patients, n=188 P value 
Experienced health, No. (%)   0.633 
 Excellent 12 (25.0) 45 (24.1)  
 Good 30 (62.5) 104 (55.6)  
 Moderate 5 (10.4) 34 (18.2)  
 Poor 1 (2.1) 4 (2.1)  
Concerns about health, No. (%)   0.137 
 None or minor 42 (89.4) 148 (80.0)  
 Moderate or severe 5 (10.6) 37 (20.0)  
Symptoms related to celiac disease a, No. (%) 10 (20.8) 44 (24.2) 0.627 
Daily life restrictions b, No. (%) 21 (46.7) 87 (47.0) 0.965 
Adherence to gluten-free diet, No. (%)   0.143 
 Strict 35 (72.9) 150 (80.2)  
 Occasional lapses 7 (14.6) 24 (12.8)  
 Regular lapses c 6 (12.5) 8 (4.3)  
 No diet 0 (0.0) 5 (2.7)  
Follow-up of celiac disease, No. (%)   0.467 
 Regular 14 (29.2) 45 (24.1)  
 None or occasional 34 (70.8) 142 (75.9)  
a Self-assessment; b Experienced to be caused by celiac disease; c Lapses every week to month. 
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Table 4. Current characteristics in subgroups of asymptomatic and symptomatic screen-
detected celiac disease patients diagnosed in childhood. 
 Screen-detected  
 Asymptomatic, n=27 Symptomatic, n=21 P value 
Age, median (IQR), years 27.7 (24.5, 35.6) 25.5 (20.2, 36.8) 0.513 
Celiac disease in the family, No. (%) 22 (81.5) 16 (76.2) 0.729 
Celiac disease-associated condition a, No. (%) 12 (44.4) 6 (28.6) 0.260 
Other concomitant disease b, No. (%) 12 (44.4) 12 (57.1) 0.383 
One or more children, No. (%) 10 (37.0) 8 (38.1) 0.940 
Experienced health, No. (%)   0.424 
 Excellent 5 (18.5) 7 (33.3)  
 Good 17 (63.0) 13 (61.9)  
 Moderate 4 (14.8) 1 (4.8)  
 Poor 1 (3.7) 0 (0.0)  
Concerns about health, No. (%)   0.063 
 None or minor 22 (81.5) 20 (100)  
 Moderate or severe 5 (18.5) 0 (0.0)  
Symptoms related to celiac disease c, No. (%) 6 (22.2) 4 (19.0) 1.000 
Daily life restrictions d, No. (%) 11 (45.8) 10 (47.6) 0.905 
Adherence to gluten-free diet, No. (%)   0.936 
 Strict 20 (74.1) 15 (71.4)  
 Occasional lapses 4 (14.8) 3 (14.3)  
 Regular lapses c 3 (11.1) 3 (14.3)  
 No diet 0 (0.0) 0 (0.0)  
Follow-up of celiac disease, No. (%)   0.174 
 Regular 10 (37.0) 4 (19.0)  
 None or occasional 17 (63.0) 17 (81.0)  
a Type 1 diabetes and/or thyroidal disease; b For example other gastrointestinal disease, rheumatic disease, hypertension, 
cancer, osteoporosis, psoriasis, depression, eating disorder or asthma; c Self-assessment; d Experienced to be caused by 
celiac disease; e Lapses every week to month. 
IQR, interquartile range. 
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eTable 1. Characteristics at celiac disease diagnosis in adults answering and not answering 
the study questionnaires. 
   Questionnaires answered   
 Yes, n=237 No, n=322 P value 
Current age, median (IQR), years 27.0 (22.0, 37.6) 25.9 (21.3, 34.7) 0.130 
Age at diagnosis, median (IQR), years 9.7 (5.3, 13.6) 10.1 (6.4, 13.0) 0.529 
Year of diagnosis, median (IQR) 1998 (1986, 2004) 1999 (1990, 2005) 0.075 
Girls, No. (%) 164 (69.2) 167 (51.9) <0.001 
Main clinical presentation, No. (%)   0.259 
 Gastrointestinal 123 (52.1) 142 (45.1)  
 Extra-intestinal 65 (27.5) 98 (31.1)  
 Risk-group screening 48 (20.3) 75 (23.8)  
Symptoms a, No. (%) 172 (76.8) 226 (75.6) 0.750 
 In risk-group screened, No. (%) 21 (44.7) 43 (57.3) 0.173 
Poor growth, No. (%) 97 (44.7) 115 (38.6) 0.164 
Body mass index, median (IQR) 16.5 (15.2, 18.4) c 16.6 (15.4, 19.3) d 0.264 
Anemia, No. (%) 63 (28.4) 63 (23.2) 0.194 
Hemoglobin, median (IQR), g/l 124 (115, 131) e 127 (118, 134) f 0.051 
Severity of villous atrophy, No. (%)   0.766 
 Partial 67 (31.5) 98 (33.6)  
 Subtotal 84 (39.4) 106 (36.3)  
 Total 62 (29.1) 88 (30.1)  
Type 1 diabetes, No. (%) 16 (8.8) 40 (15.9) 0.029 
Celiac disease in the family b, No. (%) 75 (56.0) g 87 (44.2) h 0.035 
a Asymptomatic signs such as poor growth, anemia and other laboratory abnormalities excluded; b First degree relatives; c-h Data 
available only from c 160, d 223, e 190, f 223, g 134 and h 197 of patients. 
IQR, interquartile range. 
